136 related articles for article (PubMed ID: 30769874)
1. Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
Cona MS; Lecchi M; Cresta S; Damian S; Del Vecchio M; Necchi A; Poggi MM; Raggi D; Randon G; Ratta R; Signorelli D; Vernieri C; de Braud F; Verderio P; Di Nicola M
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30769874
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Banna GL; Signorelli D; Metro G; Galetta D; De Toma A; Cantale O; Banini M; Friedlaender A; Pizzutillo P; Garassino MC; Addeo A
Transl Lung Cancer Res; 2020 Aug; 9(4):1533-1542. PubMed ID: 32953525
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
9. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
[TBL] [Abstract][Full Text] [Related]
10. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
Cortellini A; Bersanelli M; Buti S; Cannita K; Santini D; Perrone F; Giusti R; Tiseo M; Michiara M; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Rastelli F; Pergolesi F; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; De Giglio A; Iacono D; Gelibter A; Occhipinti MA; Parisi A; Porzio G; Fargnoli MC; Ascierto PA; Ficorella C; Natoli C
J Immunother Cancer; 2019 Feb; 7(1):57. PubMed ID: 30813970
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
Nosrati A; Tsai KK; Goldinger SM; Tumeh P; Grimes B; Loo K; Algazi AP; Nguyen-Kim TDL; Levesque M; Dummer R; Hamid O; Daud A
Br J Cancer; 2017 Apr; 116(9):1141-1147. PubMed ID: 28324889
[TBL] [Abstract][Full Text] [Related]
12. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Botticelli A; Cirillo A; Scagnoli S; Cerbelli B; Strigari L; Cortellini A; Pizzuti L; Vici P; De Galitiis F; Di Pietro FR; Cerbelli E; Ghidini M; D'Amati G; Della Rocca C; Mezi S; Gelibter A; Giusti R; Cortesi E; Ascierto PA; Nuti M; Marchetti P
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32353934
[TBL] [Abstract][Full Text] [Related]
13. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
Pasello G; Pavan A; Attili I; Bortolami A; Bonanno L; Menis J; Conte P; Guarneri V
Cancer Treat Rev; 2020 Jul; 87():102031. PubMed ID: 32446182
[TBL] [Abstract][Full Text] [Related]
14. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
Nakamura Y
Front Med (Lausanne); 2019; 6():119. PubMed ID: 31192215
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.
Eso Y; Seno H
Therap Adv Gastroenterol; 2020; 13():1756284820948773. PubMed ID: 32913444
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.
Lecis D; Sangaletti S; Colombo MP; Chiodoni C
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31060225
[TBL] [Abstract][Full Text] [Related]
20. Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach.
Grigorieva J; Asmellash S; Net L; Tsypin M; Roder H; Roder J
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
